Our Pipeline

BlueRock is building a pipeline of diversified therapeutic programs with blockbuster potential.

Research

Preclinical

Phase I/II

Neurodegenerative Disorders

Parkinson's Disease - Phase I/II

Undisclosed Indication - Preclinical

Undisclosed Indication - Preclinical

Undisclosed Indication - Research

Cardiovascular Disorders

Congestive Heart Failure - Phase I/II

Undisclosed Indication - Preclinical

Parkinson’s Disease

Through our Parkinson’s program, we are developing dopaminergic neurons that can replace the dopamine-secreting cells that have been lost in Parkinson’s patients. We plan to submit an Investigational New Drug (IND) application to the FDA in 2018, with the goal of treating the first patient that year. Our clinical program is now recruiting patients.

  • Parkinson’s is a degenerative disease that affects more than 10 million patients worldwide.

  • Incidence increases with age, but an estimated 4 percent of people with Parkinson’s are diagnosed before age 50.

  • The combined direct and indirect cost of Parkinson’s is estimated at $25 billion per year in the U.S. alone.

  • There is no cure for Parkinson’s, only therapies that treat symptoms or seek to slow disease progression.

Cardiac Diseases

BlueRock’s cardiac program seeks to replace heart muscle in patients who have lost muscle cells after a heart attack (myocardial infarction) or are suffering from chronic heart failure; both are leading causes of morbidity and mortality worldwide. Our science shows promise for improving and restoring the electrical and contractile function of injured hearts by introducing heart muscle cells (cardiomyocytes) that are derived from pluripotent stem cells.

  • Heart disease is the leading cause of death for men and women.

  • About 610,000 people die of heart disease in the U.S. every year, according to the CDC. That’s one in every four deaths.

  • Every year, about 735,000 Americans experience a heart attack.

  • Coronary heart disease is the most common form of heart disease, killing over 370,000 people annually.

  • There is no cure for heart disease, only therapies that treat symptoms or seek to slow disease progression.

BlueRock intends to expand its pipeline to include additional indications, addressing other diseases that are rooted in cell loss and the body’s inability to self-repair.

Contact Us

Over the next 12 months, BlueRock will be significantly expanding staff at all locations. Contact us to learn about our rewarding career opportunities in New York, Boston/Cambridge, and Toronto.

Toronto, ON
BlueRock Toronto
MaRS Discovery District
101 College Street, East Tower, 15-701 Toronto, ON
M5G 1L7, Canada

New York, NY
BlueRock New York
Alexandria Center for Life Science
450 E 29th Street, Suite 504
New York, NY 10016, USA

Cambridge, MA
BlueRock Corporate Headquarters
1 Broadway
Cambridge, MA 02142, USA

Receive Corporate Updates